Literature DB >> 10639480

Human monocyte receptors involved in tumor necrosis factor responses to group B streptococcal products.

M Cuzzola1, G Mancuso, C Beninati, C Biondo, C von Hunolstein, G Orefici, T Espevik, T H Flo, G Teti.   

Abstract

Several group B streptococcal products have been previously found to stimulate human monocytes to produce tumor necrosis factor alpha. In order to identify the receptors involved in these responses, monocytes were stimulated with purified group- or type-specific carbohydrates or lipoteichoic acid in the presence of anti-receptor monoclonal antibodies, soluble CD14, or lipopolysaccharide-binding protein. Results indicate that CD14 plays an important role in tumor necrosis factor alpha responses to all of the stimuli tested. Moreover, both CD14 and complement receptor type 3 may be involved in responses to the group-antigen.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10639480      PMCID: PMC97239          DOI: 10.1128/IAI.68.2.994-998.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  Interleukin-6 production by human neonatal monocytes stimulated by type III group B streptococci.

Authors:  J G Vallejo; C J Baker; M S Edwards
Journal:  J Infect Dis       Date:  1996-08       Impact factor: 5.226

2.  Interleukin-10 protects neonatal mice from lethal group B streptococcal infection.

Authors:  V Cusumano; F Genovese; G Mancuso; M Carbone; M T Fera; G Teti
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

3.  CD14 is a cell-activating receptor for bacterial peptidoglycan.

Authors:  D Gupta; T N Kirkland; S Viriyakosol; R Dziarski
Journal:  J Biol Chem       Date:  1996-09-20       Impact factor: 5.157

4.  Adherence of group B streptococci to adult and neonatal epithelial cells mediated by lipoteichoic acid.

Authors:  G Teti; F Tomasello; M S Chiofalo; G Orefici; P Mastroeni
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

5.  LPS induces CD14 association with complement receptor type 3, which is reversed by neutrophil adhesion.

Authors:  D M Zarewych; A L Kindzelskii; R F Todd; H R Petty
Journal:  J Immunol       Date:  1996-01-15       Impact factor: 5.422

6.  Lipoteichoic acid preparations of gram-positive bacteria induce interleukin-12 through a CD14-dependent pathway.

Authors:  M G Cleveland; J D Gorham; T L Murphy; E Tuomanen; K M Murphy
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

7.  Roles of the bacterial cell wall and capsule in induction of tumor necrosis factor alpha by type III group B streptococci.

Authors:  J G Vallejo; C J Baker; M S Edwards
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

8.  Beneficial effects of interleukin-6 in neonatal mouse models of group B streptococcal disease.

Authors:  G Mancuso; F Tomasello; M Migliardo; D Delfino; J Cochran; J A Cook; G Teti
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

9.  Antibodies to tumor necrosis factor-alpha: use as adjunctive therapy in established group B streptococcal disease in newborn rats.

Authors:  L B Givner; L Gray; T M O'Shea
Journal:  Pediatr Res       Date:  1995-10       Impact factor: 3.756

10.  CD14 enhances cellular responses to endotoxin without imparting ligand-specific recognition.

Authors:  R L Delude; R Savedra; H Zhao; R Thieringer; S Yamamoto; M J Fenton; D T Golenbock
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

View more
  9 in total

1.  Interleukin-10 regulates the tissue factor activity of monocytes in an in vitro model of bacterial endocarditis.

Authors:  M H Veltrop; J A Langermans; J Thompson; M J Bancsi
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

Review 2.  Interaction of neonatal phagocytes with group B streptococcus: recognition and response.

Authors:  Philipp Henneke; Reinhard Berner
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

3.  Role of monocytes in experimental Staphylococcus aureus endocarditis.

Authors:  M H Veltrop; M J Bancsi; R M Bertina; J Thompson
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

4.  Involvement of CD14 and beta2-integrins in activating cells with soluble and particulate lipopolysaccharides and mannuronic acid polymers.

Authors:  T H Flo; L Ryan; L Kilaas; G Skjâk-Braek; R R Ingalls; A Sundan; D T Golenbock; T Espevik
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

5.  CD14-dependent and -independent cytokine and chemokine production by human THP-1 monocytes stimulated by Streptococcus suis capsular type 2.

Authors:  M Segura; N Vadeboncoeur; M Gottschalk
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

6.  Elevated levels of lipopolysaccharide-binding protein and soluble CD14 in plasma in neonatal early-onset sepsis.

Authors:  Reinhard Berner; Birgitt Fürll; Felix Stelter; Jana Dröse; Hans-Peter Müller; Christine Schütt
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

7.  Interleukin-18 is an essential element in host resistance to experimental group B streptococcal disease in neonates.

Authors:  Vitaliano Cusumano; Angelina Midiri; Valentina Valeria Cusumano; Antonella Bellantoni; Giuseppe De Sossi; Giuseppe Teti; Concetta Beninati; Giuseppe Mancuso
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  Critical role of the complement system in group B streptococcus-induced tumor necrosis factor alpha release.

Authors:  Ofer Levy; Rochelle M Jean-Jacques; Colette Cywes; Richard B Sisson; Kol A Zarember; Paul J Godowski; Jennifer L Christianson; Hilde-Kari Guttormsen; Michael C Carroll; Anne Nicholson-Weller; Michael R Wessels
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

Review 9.  Induction and termination of inflammatory signaling in group B streptococcal sepsis.

Authors:  Julia Wennekamp; Philipp Henneke
Journal:  Immunol Rev       Date:  2008-10       Impact factor: 12.988

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.